Back

Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

Bhiman, J. N.; Richardson, S. I.; Lambson, B. E.; Kgagudi, P.; Mzindle, N.; Kaldine, H.; Crowther, C.; Gray, G.; Bekker, L.-G.; Koen, A.; Fairlie, L.; Fouche, L.; Bhorat, Q.; Dheda, K.; Tameris, M.; Masilela, M. S. L.; Hoosain, Z.; Singh, N.; Hanley, S.; Archary, M.; Louw, C.; Grobbelaar, C.; Lalloo, U.; Joseph, N.; Kruger, G.; Shinde, V.; Bennett, C.; Glenn, G.; Madhi, S.; Moore, P. L.

2022-07-17 immunology
10.1101/2022.07.14.500148 bioRxiv
Show abstract

The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4/5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT: 1,197) and BA.4 (GMT: 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine. These data are of particular relevance as BA.4 is emerging to become the dominant strain in many locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
npj Vaccines
○ 67 papers in training set
Top 0.1%
18.4%
Similar papers in this journal
2
Nature Medicine
○ 125 papers in training set
Top 0.2%
7.9%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 21%
7.9%
Similar papers in this journal
4
Vaccine
○ 203 papers in training set
Top 0.6%
5.5%
Similar papers in this journal
5
Med
○ 39 papers in training set
Top 0.1%
5.5%
Similar papers in this journal
6
eBioMedicine
○ 183 papers in training set
Top 0.5%
4.8%
7
The Lancet Infectious Diseases
○ 73 papers in training set
Top 0.2%
4.3%
50% of probability mass above
8
Cell Reports Medicine
○ 153 papers in training set
Top 1%
2.6%
9
Scientific Reports
○ 3612 papers in training set
Top 41%
2.4%
10
Frontiers in Immunology
○ 638 papers in training set
Top 5%
2.1%
11
The Journal of Infectious Diseases
◐ 202 papers in training set
Top 2%
1.9%
12
Vaccines
○ 198 papers in training set
Top 2%
1.7%
13
iScience
○ 1154 papers in training set
Top 17%
1.7%
14
Emerging Microbes & Infections
○ 74 papers in training set
Top 0.7%
1.7%
15
Cell Reports
○ 1498 papers in training set
Top 19%
1.7%
16
Human Vaccines & Immunotherapeutics
○ 25 papers in training set
Top 0.3%
1.4%
17
Gut
● 40 papers in training set
Top 0.6%
1.3%
18
JAMA Network Open
● 130 papers in training set
Top 3%
1.1%
19
Microbiology Spectrum
● 469 papers in training set
Top 9%
1.1%
20
New England Journal of Medicine
● 52 papers in training set
Top 0.4%
1.1%
21
eLife
● 5828 papers in training set
Top 59%
1.1%
22
Nature
○ 645 papers in training set
Top 8%
1.1%
23
mBio
● 833 papers in training set
Top 10%
1.0%
24
Molecular Therapy
○ 81 papers in training set
Top 2%
1.0%
25
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.6%
0.9%
26
PLOS Pathogens
● 820 papers in training set
Top 9%
0.8%
27
JAMA
● 18 papers in training set
Top 0.5%
0.6%
28
Clinical Infectious Diseases
◐ 235 papers in training set
Top 3%
0.6%
29
PLOS ONE
● 5266 papers in training set
Top 62%
0.6%
30
The Lancet Microbe
○ 44 papers in training set
Top 0.9%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.